Journal of Clinical Oncology
Articles in this Issue
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
LBA4 Background: In the prespecified interim analysis of progression-free survival (PFS) from the HARMONi-6 study, ivonesc...
Adjuvant aspirin for stage III colorectal cancer after curative resection: Primary analysis of the randomized double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C).
LBA3508 Background: Observational studies suggest aspirin benefits in colorectal cancer (CRC), but adjuvant evidence remai...
Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.
LBA660 Background: THP ± Cb represent the standard neoadjuvant treatment for HER2-positive breast cancer. Despite achievin...
Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial.
LBA4511 Background: RAMPART is evaluating one year of immune checkpoint inhibitor therapy versus active monitoring in pati...
TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.
LBA5007 Background: In the Phase 3 TALAPRO-2 trial, adding the poly(ADP-ribose) polymerase inhibitor TALA to the androgen-...
Safety and dosimetry of <sup>177</sup> Lu-rosopatamab tetraxetanplus SoC in patients with metastatic castration-resistant prostate cancer: Preliminary results from part 1 of phase 3 ProstACT Global study.
LBA5009 Background: ProstACT Global is a Phase 3 study of 177 Lu-rosopatamab + sta...
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by D2 gastrectomy and adjuvant chemotherapy for locally advanced gastric cancer (Neo-CRAG): A randomized, multicenter, phase 3 trial.
LBA4075 Background: Neoadjuvant chemoradiotherapy (CRT) has been proposed to improve tumor response over neoadjuvant chemo...
Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial.
LBA6500 Background: Myelofibrosis (MF) is a debilitating myeloproliferative neoplasm marked by splenomegaly, constitutiona...
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2-expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial.
LBA4026 Background: For patients (pts) with HER2-high (defined as IHC 3+, or IHC 2+/FISH+ based on Chinese CSCO GC guideli...
Low-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial.
LBA1510 Background: Pembrolizumab plus Platinum doublet chemotherapy is the standard of care for advanced non-small cell l...
Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).
LBA4000 Background: TACE, a global standard of care (SoC) for unresectable eeHCC, induces a tumor immune response. STRIDE...
MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.
LBA9514 Background: Advanced Merkel cell carcinoma (MCC) often responds to anti-PD-(L)1, but patients (pts) with immune ch...
Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.
LBA1018 Background: In Asia, BC incidence is increasing and peaks before menopause; tamoxifen is commonly used for pre/per...
A multicenter, randomized, controlled, open-label, phase II trial of autologous tumor-infiltrating lymphocytes (GC101 TIL) in patients with advanced melanoma.
LBA9509 Background: Tumor-infiltrating lymphocyte (TIL) therapy is effective in advanced melanoma but hampered by toxicity...
Preliminary injection site reaction immune response results from open-label arm of ongoing phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy (Flamingo-01).
LBA538 Background: This phase III trial is a prospective, randomized, double-blinded, multi-center study (NCT05232916) in...
Gabapentin plus tramadol versus tramadol alone for chemoradiotherapy-induced oral mucositis pain in head and neck cancer: Results of a randomized phase III trial.
LBA12001 Background: Oral mucositis-related pain during concurrent chemoradiation (CTRT) for head and neck squamous cell c...
Primary results of the BETTER-CARE trial: Implementation of a needs-adapted and individualized follow-up care after primary breast cancer.
LBA510 Background: Follow-up care after primary breast cancer is a central component of oncological care and is gaining im...
Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.
LBA514 Background: Preclinical and clinical data show that antibody-drug conjugates (ADCs) such as T-DXd may synergize wit...
Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial.
LBA503 Background: Axillary lymph node dissection (ALND) causes arm-related morbidity. The SENOMAC trial evaluates whether...
Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.
LBA2000 Background: Post-operative stereotactic radiation (SRT) is the standard to reduce recurrence of resected brain met...
Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population.
LBA10509 Background: The MCED test (Galleri) detects a shared cancer signal from cell-free DNA in blood and predicts a can...
Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study.
LBA1 Background: RP is potentially curative for patients (pts) with HR LPC/LAPC, yet ≈50% of pts relapse. PROTEUS...
Neoadjuvant intralesional daromun (L19IL2/L19TNF) in resectable locally advanced melanoma: An update on the primary outcome and sensitivity analyses (EFS) from the PIVOTAL phase 3 trial.
LBA9517 Background: PIVOTAL (NCT02938299) is an open-label, randomized, multicenter, phase 3 trial evaluating daromun as a...
Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174.
LBA9505 Background: EA6174 (STAMP) is the first randomized phase III trial of adjuvant pembrolizumab (pembro) in resected...
A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/ <i>PIK3CA</i> -mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2).
LBA1008 Background: Current standard treatment (tx) for patients (pts) with HR+/HER2-/ PIK3CA...